Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
Rhea-AI Summary
Ultragenyx (NASDAQ: RARE) will host a conference call on Tuesday, May 5, 2026 at 5:00 p.m. ET to discuss first quarter 2026 financial results and provide a corporate update. The live webcast and a replay (available for three months) will be on the company's investor website.
Positive
- None.
Negative
- None.
News Market Reaction – RARE
In the Apr 29 session, RARE declined 1.43%, reflecting a mild negative market reaction. Argus tracked a peak move of +7.1% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-02-05 | Earnings call notice | Neutral | +3.8% | Scheduled Q4 and full-year 2025 earnings and corporate update call. |
| 2025-10-28 | Earnings call notice | Neutral | -0.5% | Announced Q3 2025 results and corporate update conference call. |
| 2025-07-30 | Earnings call notice | Neutral | -1.9% | Scheduled Q2 2025 earnings and corporate update webcast. |
| 2025-04-30 | Earnings call notice | Neutral | -0.0% | Set date for Q1 2025 financial results and corporate update call. |
| 2025-02-06 | Earnings call notice | Neutral | -0.9% | Announced Q4 and full-year 2024 earnings and corporate update call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings call announcements under the same tag showed small, mixed price reactions, with an average move of 0.09% and no strong directional pattern.
Over the past year, Ultragenyx has repeatedly issued similar notices scheduling earnings and corporate update calls, typically at 5:00 p.m. ET with three-month replays via its investor website. These announcements, covering quarterly and full-year results for 2024 and 2025, produced modest next-day moves ranging from a small gain of 3.83% to slight declines. The current first-quarter 2026 call notice continues this established communication pattern without adding new financial figures or clinical disclosures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, May 5, 2026, to discuss its financial results and corporate update for the quarter ending March 31, 2026.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors
Joshua Higa
ir@ultragenyx.com
Media
Jess Rowlands
media@ultragenyx.com
